Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.38 |
| ▸ | F2 | P00734 | 3/20 | 0.32 |
| ▸ | F11 | P03951 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14273367 | 0.89 | F10 (0.36) | F10F2 | |
| SCHEMBL1640705 | 0.89 | F10 (0.36) | F10F2 | |
| SCHEMBL1640301 | 0.89 | F10 (0.39) | F10F2F11 | |
| SCHEMBL1640628 | 0.89 | F10 (0.37) | F10TP53 | |
| SCHEMBL1639115 | 0.87 | F10 (0.42) | F10F2 | |
| SCHEMBL1639790 | 0.87 | F10 (0.35) | F10F2 | |
| SCHEMBL12727560 | 0.87 | F10 (0.37) | F10F2F11 | |
| SCHEMBL1640707 | 0.84 | F10 (0.36) | F10 | |
| SCHEMBL1639103 | 0.83 | EGFR (0.35) | F10LMNA | |
| SCHEMBL3835105 | 0.78 | ROCK2 (0.36) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094272-B1 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARM INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20110098247-A1 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098247-A1 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors | TBXA2R, F2R, PTGER1 | F10 972/4885F2 65/4885F11 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.